Navigation Links
Pioneer Award recipients Robin Ali, Ph.D., Jean Bennett, M.D., Ph.D., and William Hauswirth, Ph.D.
Date:9/3/2014

New Rochelle, NY, September 3, 2014Robin Ali, PhD, University College London, Jean Bennett, MD, PhD, Perelman School of Medicine, University of Pennsylvania, and William Hauswirth, PhD, University of Florida College of Medicine, are co-recipients of the Pioneer Award, recognized for their leadership and contributions to the field of gene therapy to treat retinal degeneration leading to blindness. Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, is commemorating its 25th anniversary by bestowing this honor on the leading Pioneers in the field of cell and gene therapy selected by a blue ribbon panel* and publishing a Pioneer Perspective by the award recipients.

Dr. Ali, Professor of Human Molecular Genetics, led proof-of-concept studies demonstrating the feasibility of using gene therapy to repair photoreceptor defects in the eye and of using cell transplantation for retinal repair. He also had a pioneering role in the first clinical trial for inherited retinal degeneration.

Dr. Bennett, Professor of Ophthalmology, Cell and Developmental Biology, recalls her first experiences with molecular biology and gene transfer technology, acquired in the lab of Dr. W. French Anderson, known as "the father of gene therapy." She describes her developing career, including the decision to go to medical school and to focus her research on developing adeno-associated virus (AAV) gene therapy techniques for restoring vision to patients affected by retinal degeneration in her Pioneer Perspective article entitled "My Career Path for Developing Gene Therapy for Blinding Diseases: The Importance of Mentors, Collaborators, and Opportunities," available on the Human Gene Therapy website.

Dr. Hauswirth, Rybaczki-Bullard Professor of Ophthalmology, traces his involvement in the field of retinal gene therapy to his early interest in studying the interaction between light and biological molecules. He provides a historical perspective on the discovery of the gene mutations responsible for several of the most common inherited eye diseases and the advances in AAV gene therapy technology being developed and applied to deliver replacement genes. His Pioneer Perspective, entitled "Retinal Gene Therapy Using Adeno-Associated Viral Vectors: Multiple Applications for a Small Virus," is available on the Human Gene Therapy website.

"These groups brought forward the first convincing clinical results of in vivo gene therapy, which paved the way for the current renaissance we are seeing in the field," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


'/>"/>

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground
2. Pioneer in next generation sequencing receives 2014 HudsonAlpha Life Sciences Prize
3. Christof von Kalle, M.D., Ph.D. receives Pioneer Award
4. Frederic Bushman, Ph.D. receives Pioneer Award for advancing therapeutic gene delivery methods
5. NJIT researchers probe links between vision problems and cognition in a pioneering study
6. Celebrating the work of a neglected scientific pioneer
7. Pioneering forensics research into body fluids in sexual assaults
8. James Wilson, M.D., Ph.D. receives Pioneer Award
9. Pioneering findings on the dual role of carbon dioxide in photosynthesis
10. Why didnt these pioneers of medicine receive a Nobel Prize?
11. Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for immunodeficiency disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pioneer Award recipients Robin Ali, Ph.D., Jean Bennett, M.D., Ph.D., and William Hauswirth, Ph.D.
(Date:10/4/2017)...  GCE Solutions, a global clinical research organization (CRO), announces the ... on October 4, 2017. Shadow is designed to assist medical writers ... 0070 of the European Medicines Agency (EMA) in meeting the requirements ... ... ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family ... and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... and administered by the New York Academy of Sciences to honor the excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
Breaking Biology Technology: